Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might ...
Just last week, Tesla laid off yet another round of workers. This time, however, Tesla gutted an entire team. Around 500 ...
Amgen (NASDAQ: AMGN) is one of the top drugmakers in the world, with a market value north of $140 billion. The company has been expanding its business via acquisitions in recent years as it looks ...
Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...
April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due to poor U.S. sales of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira.
Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 13 unusual trades. Delving into the details, we found 46% of traders were ...
Amgen's acquisition of Horizon Therapeutics has made it a major player in the rare disease space, with potential for long-term shareholder return. The company has key pipeline milestones in 2024 ...
Walking Fish Therapeutics has closed after a lead investor backed out of a critical series B round. CEO Rusty Williams, M.D., Ph.D., said in an interview with Fierce Biotech that the company was on ...
The FDA told Amgen to test whether a quarter-dose of sotorasib worked as well as the amount on the label. It did, but the biotech is sticking to the higher dose, which earns it an extra $180,000 a ...
Amgen still needs to show that the reduction in Lp(a) is accompanied by lower rates of cardiovascular outcomes, and will endeavour to show that in its phase 3 programme which will start to enrol ...
Stocks Rally As Jobs Report Rekindles Rate Cut Hopes, Apple Rockets, Bitcoin Soars Above $61,000: What's Driving Markets Friday? A weaker-than-expected jobs report sparked a widespread market ...
(Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira. The ...